A Degarelix Trial in Patients With Prostate Cancer

• Status: Terminated
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Goserelin

Criteria

Inclusion Criteria:

• Has given written consent prior to any trial-related activity is performed. (A trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient).

• Has completed the CS35 trial.

Exclusion Criteria:

• Has been withdrawn from the CS35 trial.

• Has had end of trial visit in CS35 prior to approval of the CS35A protocol.